Median survival was not reached, but the Kaplan-Meier estimate of 25% survival (i.e., the timepoint where 25% of the study population survived) was greater in patients with stage II NSCLC with PD-L1 TC<25% compared with those with PD-L1 TC ≥25%; however, among patients with stage IIIA NSCLC, those with PD-L1 TC ≥25% demonstrated longer survival (S1 Table). Here, CD274 is linked to non-small cell lung carcinoma.